香港交易及結算所有限公司及聯交所對本報告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示概不就因本報告全部或任何部分內容而產生或因倚賴該等內容 而引致的任何損失承擔任何責任。 本報告乃遵照聯交所GEM《證券上市規則》（「《GEM上市規則》」）的規定提供有關中生北控生 物科技股份有限公司（「本公司」或「中生北控」，與其附屬公司統稱為「本集團」）的資料，本公 司各董事（「董事」）願就本報告共同及個別承擔全部責任。各董事經作出一切合理查詢後確 認，就彼等所深知及確信：(1)本報告所載資料在各重大方面均屬準確完整，且無誤導或欺詐 成分；及(2)本報告並無遺漏其他事項，致使本報告所載任何聲明或本報告產生誤導。 中生北控生物科技股份有限 公 司 BIOSINO BIO-TECHNOLOGY AND SCIENCE INCORPORATION 第一季度業績報告 2023 | AFU ua | | | --- | --- | | 2 0 | NORD (CNKERS) | | 200 | | | g i ક્ષિમ | | | No 12 O STEPHIL SEARCH FRE | | 中生北控生物科技股份 ...

中 生 北 控 生 物科 技 股 份 有 限 公司 BIOSINO BIO-TECHNOLOGY AND SCIENCE INCORPORATION （於中華人民共和國註冊成立的股份有限公司） 8247 （股份代號： ） 截至二零二三年三月三十一日止三個月 第一季度業績公佈 GEM 香港聯合交易所有限公司 的特色 GEM 的定位，乃為相比起其他在香港聯合交易所有限公司（「聯交所」）上市的公司帶有較高投 資風險的公司提供一個上市的市場。有意投資的人士應了解投資於該等公司的潛在風險，並 GEM GEM 應經過審慎周詳的考慮後方作出投資決定。 的較高風險及其他特色表示 較適合專 業及其他老練投資者。 GEM GEM 由於 上市公司新興的性質所然，在 買賣的證券可能會較於聯交所主板買賣之證券 GEM 承受較大的市場波動風險，同時無法保證在 買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本公佈的內容概不負責，對其準確性或完整性亦不發 表任何聲明，並明確表示概不就因本公佈全部或任何部分內容而產生或因倚賴該等內容而引 致的任何損失承擔任何責任。 GEM GEM 本公佈乃遵照聯交所 《證券上市規則》（「《 ...

中生北控生物科技股份有限 公 司 BIOSINO BIO-TECHNOLOGY AND SCIENCE INCORPORATION 年報 2022 | 0.2-14-10 | | | | --- | --- | --- | | Callery Control Concession Concession Concession Concession Concession Concession of | FOULTS | | | becamed annual a control to | | | | A | | | | 16.2 ROBER (SUBSCHIPS) (STATE | | | | - 1 4 - 11 | | | | (5) (8) 1,7,80 | | | | -2 NOWE | | COMITS | | 2011 12 11 to | A C Real Property | | | .. | | | --- | --- | | 1 | AFUL | | 资博首荷 | | | | 2019 11:27 | | 5007 = . | | | 2596 | | | 東日本市の中国の | MAN (R) ...

Financial Performance - For the three months ended September 30, 2022, the company reported revenue of RMB 103,223,000, an increase of 18.5% compared to RMB 87,072,000 for the same period in 2021[12]. - The gross profit for the third quarter of 2022 was RMB 45,757,000, representing a gross margin of approximately 44.3%[12]. - The net profit for the three months ended September 30, 2022, was RMB 12,645,000, compared to RMB 6,662,000 for the same period in 2021, indicating an increase of 90.0%[12]. - The earnings per share attributable to the parent company for the third quarter of 2022 was RMB 0.07, up from RMB 0.04 in the same quarter of 2021[12]. - For the nine months ended September 30, 2022, the company achieved total revenue of RMB 275,659,000, a growth of 5.3% from RMB 261,737,000 in the same period of 2021[12]. - The company reported a net profit of RMB 17,377,000 for the nine months ended September 30, 2022, compared to RMB 11,829,000 for the same period in 2021, reflecting an increase of 47.2%[12]. - The total comprehensive income for the three months ended September 30, 2022, was RMB 12,645,000, compared to RMB 6,638,000 for the same period in 2021[15]. Research and Development - Research and development expenses for the third quarter of 2022 were RMB 11,220,000, compared to RMB 9,962,000 in the same quarter of 2021, indicating a rise of 12.6%[12]. - The company aims to enhance product quality and develop new testing projects in line with industry technological advancements[37]. - The company's R&D investment for the first three quarters was over RMB 18.66 million, resulting in four patent grants during the reporting period[38]. Market Presence and Strategy - The company continues to focus on the research, development, production, and distribution of in vitro diagnostic reagent products, which remains its core business[19]. - The company aims to enhance its market presence and expand its product offerings in the in vitro diagnostics sector[19]. - The company reported a slight increase in revenue and profit compared to the same period last year due to participation in domestic pandemic prevention-related business[37]. - The company has achieved approximately 70% domestic substitution in biochemical diagnostic reagents, with the market size expected to reach RMB 11 billion[35]. - The company plans to optimize supplier relationships and direct procurement to continuously reduce raw material and overall costs[36]. Shareholder Information - The company's basic earnings per share for the nine months ended September 30, 2022, was calculated based on a weighted average of 144,707,176 shares, with no adjustments for potential diluted shares[27]. - As of September 30, 2022, Mr. Wu Lebin holds 3,500,878 shares, representing 4.35% of the company's domestic shares and 2.42% of the total registered capital[41]. - Beijing Puxai Asset Management Co., Ltd. directly holds 31,308,576 shares, accounting for 38.93% of the domestic shares and 21.64% of the total registered capital[44]. - Yunnan Shengneng Investment Partnership holds 10,939,314 domestic shares and 6,780,000 H shares, representing 13.60% and 10.55% of the respective categories[44]. Corporate Governance - The board of directors recommended not to distribute an interim dividend for the nine months ended September 30, 2022[30]. - The company's total reserves as of September 30, 2022, amounted to RMB 210,451,000, reflecting an increase from RMB 185,158,000 as of September 30, 2021[29]. - The Audit Committee, consisting of three independent non-executive directors, has reviewed the unaudited condensed consolidated financial statements for the period[58]. - The company has complied with all provisions of the GEM Listing Rules Appendix 15 Corporate Governance Code as of September 30, 2022, except for the provision D.2.5[59]. - The company has decided not to establish an internal audit department due to its scale and simple operational structure, but has implemented measures to fulfill internal audit functions[60]. - The board has engaged external consultants to conduct internal reviews as determined by the audit committee[60]. - The company believes that its existing organizational structure and close supervision by management ensure adequate risk management and internal control[60]. - The board will periodically review the necessity of establishing an internal audit function and may establish an internal audit team if needed[60]. Securities Transactions - The company has not purchased, sold, or redeemed any of its listed securities during the nine months ending September 30, 2022[54].

中生北控生物科技股份有限 公 司 BIOSINO BIO-TECHNOLOGY AND SCIENCE INCORPORATION (Incorporated in the People's Republic of China with limited liability) (Stock Code : 8247) 2022 Interim Report 中生北控生物科技股份有限 公 司 BIOSINO BIO-TECHNOLOGY AND SCIENCE INCORPORATION 2022 中期報告 = r 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位，乃為相比起其他在聯交所上市的公司帶有較高投資風險的公司提供一個上市 的市場。有意投資的人士應了解投資於該等公司的潛在風險，並應經過審慎周詳的考慮後 方作出投資決定。GEM的較高風險及其他特色表示GEM較適合專業及其他老練投資者。 由於GEM上市公司新興的性質所然，在GEM買賣的證券可能會較於聯交所主板買賣之證券 承受較大的市場波動風險，同時無法保證在GEM買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本報告的內容概不負責 ...

Financial Performance - The company's revenue for the first quarter of 2022 was RMB 88,560 thousand, representing an increase of 9.2% compared to RMB 80,894 thousand in the same period of 2021[17] - Gross profit for the first quarter of 2022 was RMB 34,688 thousand, with a gross margin of approximately 39.2%, compared to RMB 35,304 thousand in the first quarter of 2021[17] - The net profit for the first quarter of 2022 was RMB 2,118 thousand, a significant increase from RMB 405 thousand in the same period of 2021[17] - The company’s operating profit for the first quarter of 2022 was RMB 5,393 thousand, compared to RMB 4,100 thousand in the first quarter of 2021[17] - The company reported a total comprehensive income of RMB 2,132 thousand for the first quarter of 2022, compared to RMB 421 thousand in the same period of 2021[20] - The company’s financial costs for the first quarter of 2022 were RMB 1,290 thousand, down from RMB 1,842 thousand in the same period of 2021[17] - The company reported a tax expense of RMB 1,091,000 for the three months ended March 31, 2022, compared to RMB 1,071,000 for the same period in 2021, reflecting a slight increase of 1.87%[30] - The total tax expense for the current period reflects the preferential tax rate of 15% for high-tech enterprises, compared to the standard rate of 25% in China[30] Research and Development - Research and development expenses for the first quarter of 2022 were RMB 5,074 thousand, slightly lower than RMB 5,800 thousand in the first quarter of 2021[17] - The company obtained five patent authorizations during the reporting period, enhancing its product offerings in areas such as vitamin D testing and uric acid measurement[43] Business Focus and Market Dynamics - The company continues to focus on the production, sales, and distribution of in vitro diagnostic reagents as its main business activity[23] - The in vitro diagnostic industry is experiencing significant growth, with biochemical and immunodiagnostic reagents accounting for over 50% of market demand, driven by the need for routine medical testing[40] - The company anticipates increased competition in the in vitro diagnostic market due to evolving industry dynamics and heightened market concentration[40] - The company is committed to providing high-quality and comprehensive services to its customers, aiming for product, market, and management upgrades[41] - The company is focusing on strengthening its business foundation and adjusting operational strategies to enhance service capabilities and innovate cooperation models[41] Shareholder Information - As of March 31, 2022, Mr. Chen Peng holds 10,000,000 shares, representing 12.43% of the domestic shares and 6.91% of the total registered capital[47] - Beijing Puxi Asset Management Co., Ltd. directly holds 31,308,576 shares, accounting for 38.93% of the domestic shares and 21.64% of the total registered capital[49] - Yunnan Shengneng Investment Partnership holds 12,269,648 domestic shares, which is 15.26% of the domestic shares and 13.16% of the total registered capital[49] - The company has a significant shareholder structure, with Beijing Holdings Limited holding 27,256,143 H shares, representing 42.40% of the H shares[49] - Mr. Li Yang holds 1,050,263 shares directly, which is 1.31% of the domestic shares[49] Corporate Governance - The company has adopted a code of conduct for directors regarding securities trading, ensuring compliance with GEM Listing Rules[56] - The company has confirmed that all directors complied with the standards of conduct for securities trading during the reporting period[56] - The report indicates no new strategies or market expansions were disclosed during the earnings call[51] - The company established an audit committee on February 10, 2006, to review and supervise financial reporting procedures and internal control systems[61] - As of March 31, 2022, the company complied with all provisions of the Corporate Governance Code, except for provision D.2.5[62] - The company decided not to establish an internal audit department due to its scale and simple operational structure, but has implemented measures to fulfill internal audit functions[63] - The board has engaged external consultants to conduct internal reviews as determined by the audit committee[63] - The board will periodically review the necessity of establishing an internal audit function and may form an internal audit team if needed[63] Dividends - The company did not recommend the distribution of an interim dividend for the three months ended March 31, 2022, consistent with the previous year[35] Earnings Per Share - The earnings per share for the first quarter of 2022 were RMB (0.01), consistent with the same period in 2021[17] - The basic loss per share attributable to ordinary equity holders of the parent was calculated based on a weighted average of 144,707,176 shares for both the three months ended March 31, 2022, and 2021, with no adjustments for potential dilution[31]

Financial Performance - The company's operating revenue for the year reached approximately RMB 348 million, an increase of 7% compared to the previous year[22]. - The company's profit for the year was RMB 32 million, a significant recovery from a loss of RMB 7 million in the previous year[26]. - Gross profit for the reporting period was RMB 144 million, up 30% year-on-year, with a gross margin of 41% (2020: 34%)[48]. - The group reported a profit of approximately RMB 6,925,000 as of December 31, 2021, with no dividends recommended for the year[146][155]. - The loss attributable to the company's owners was RMB 1.14 million, down from a profit of RMB 2.72 million in the previous year, primarily due to inventory impairment losses[54]. Dividend Policy - The board of directors did not recommend the distribution of any dividends for the year ended December 31, 2021[22]. - The company has adopted a dividend policy to allow shareholders to share in the company's profits, contingent on stable earnings and no significant investments or commitments[125]. Market and Industry Focus - The company is focusing on enhancing its product offerings and expanding its market presence in the biotechnology sector[28]. - The external environment for the in-vitro diagnostic industry remains challenging due to the ongoing impact of the COVID-19 pandemic and intensified market competition[33]. - The domestic in-vitro diagnostic market is dominated by foreign companies, which hold over 50% market share, particularly in high-end hospitals[41]. - The IVD industry is expected to face increased competition and consolidation, necessitating a focus on innovation and product differentiation[59]. Research and Development - The company continues to focus on the development and introduction of medical diagnostic products, optimizing production processes to reduce costs and increase revenue[34]. - The total research and development costs for the year amounted to RMB 24.9 million, a decrease of 12% compared to RMB 28.2 million in 2020[51]. - The company is exploring innovative R&D mechanisms and has reformed its project operation mechanisms to enhance performance evaluation[34]. Corporate Governance - The board of directors consists of 7 to 9 members, including executive, non-executive, and independent non-executive directors, all of whom are responsible for overseeing the group's management and strategic direction[77]. - The company has implemented measures to ensure compliance with the GEM Listing Rules and relevant laws and regulations, despite not establishing an internal audit department due to its operational scale[76]. - The board has established mechanisms to ensure independent opinions and inputs, including the recruitment of independent non-executive directors with relevant experience[82]. - The board confirmed that the current board structure is reasonable and does not require adjustments after evaluating the skills and experience of existing directors[110]. Employee and Management Information - As of December 31, 2021, the group employed a total of 421 full-time employees in Hong Kong and China, a decrease from 450 in 2020[70]. - The total employee cost for the year ended December 31, 2021, was approximately RMB 73.04 million, compared to RMB 69.36 million in 2020, reflecting an increase of about 4.9%[70]. - The company has adopted a recruitment policy that considers diversity perspectives, including gender diversity, for senior management positions[86]. Financial Position and Debt Management - The net debt decreased by approximately RMB 30 million compared to the previous year, mainly due to cash flows from financing activities during the year[64]. - The cash and bank balances at the end of the year were RMB 4.4 million, slightly down from RMB 4.5 million in 2020[62]. - The net debt to capital ratio improved to 59% from 75% in the previous year[62]. Compliance and Transparency - The company is committed to maintaining transparency and accuracy in its financial reporting and disclosures[4]. - The company has maintained compliance with the GEM Listing Rules and all relevant laws and regulations[38]. - The company is committed to maintaining transparency and open communication with shareholders and investors through various channels[131]. Shareholding Structure - The company has a significant concentration of shareholding, with major shareholders holding substantial percentages of both domestic and H shares[171]. - The company has achieved a public float of over 25% of its total issued shares as of December 31, 2021[175]. Audit and Financial Reporting - The auditor's fee for audit services was approximately RMB 1,500,000 for the year ended December 31, 2021[123]. - The financial statements for the year 2021 were deemed to accurately reflect the company's financial position and operating results, supported by an unqualified auditor's report from Ernst & Young[189].

中生北控生物科技股份有限 公 司 BIOSINO BIO-TECHNOLOGY AND SCIENCE INCORPORATION * (Incorporated in the People's Republic of China with limited liability) (Stock Code : 8247) Third Quarterly Report 2021 * For identification purpose only 中生北控生物科技股份有限 公 司 BIOSINO BIO-TECHNOLOGY AND SCIENCE INCORPORATION * 第三季度業績報告 2021 * 僅 供 識 別 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位，乃為相比起其他在聯交所上市的公司帶有較高投資風險的公司提供一個上市 的市場。有意投資的人士應了解投資於該等公司的潛在風險，並應經過審慎周詳的考慮後 方作出投資決定。GEM的較高風險及其他特色表示GEM較適合專業及其他老練投資者。 由於GEM上市公司新興的性質所然，在GEM買賣的證券可能會較於聯交所主板買賣之證券 承受較大的市場波動 ...

Financial Performance - BIOSINO reported a significant increase in revenue, achieving RMB 150 million for the first half of 2021, representing a growth of 25% compared to the same period last year[27]. - The company achieved revenue of approximately RMB 174.7 million for the six months ended June 30, 2021, representing a growth of about 33% compared to RMB 131.4 million in the same period last year[36]. - The company’s total revenue for the six months ended June 30, 2021, was RMB 179,187,000, an increase from RMB 162,078,000 in the same period of 2020[72]. - Operating revenue for the three months ended June 30, 2021, was RMB 93,771 thousand, an increase of 11.7% from RMB 84,294 thousand in the same period of 2020[61]. - Gross profit for the six months ended June 30, 2021, reached RMB 81,034 thousand, up 73.4% from RMB 46,716 thousand in the same period of 2020[61]. - The profit attributable to shareholders was approximately RMB 1.8 million, a significant turnaround from a loss of RMB 12.3 million in the same period last year[36]. - The net profit attributable to the parent company for the three months ended June 30, 2021, was RMB 2,488 thousand, compared to RMB 3,491 thousand in the same period of 2020, reflecting a decrease of 28.8%[64]. - The company reported a significant increase in operating profit, with a net operating cash flow of RMB 25,353,000 compared to a loss of RMB 9,290,000 in the previous year[74]. Market Position and Strategy - The company expanded its distribution network to over 600 distributors across more than 30 provinces and municipalities in China, enhancing its market reach[28]. - BIOSINO aims to enhance its competitiveness by adhering to principles of innovation, quality, and legal operation, which are central to its business strategy[28]. - The company is actively pursuing new product development and technological advancements to strengthen its market position[27]. - The company is focusing on enhancing product quality standards and exploring new marketing models to adapt to market changes[37]. - The company plans to strengthen its sales team and improve after-sales service capabilities to enhance brand influence and market competitiveness[37]. - The domestic IVD market is expected to continue expanding due to increasing health awareness and improvements in medical quality and technology[44]. - The introduction of policies supporting the medical device and IVD industry is expected to further drive rapid development in the domestic market[40]. - The company is actively seeking new business growth points and expanding revenue sources to regain its leading position in the industry[51]. Research and Development - The company is focused on research and development, leveraging the strong academic background of its management team, which includes several university professors and PhDs[28]. - The company is focused on enhancing the quality of existing products and developing new testing projects driven by industry technological advancements[51]. - The company aims to improve its reagent and instrument innovation capabilities and medical diagnostic service levels to enhance overall competitiveness[51]. - The company completed 71 product renewal registrations and obtained 36 first-class filing certificates for mass spectrometry sample pretreatment and cleaning products during the reporting period[49]. - The company has received four product patents, including a stable biochemical composite calibrator and its preparation method, and an immunoturbidimetric assay kit[49]. Financial Position - As of June 30, 2021, the company's cash and bank balance was approximately RMB 22.85 million, down from RMB 45.45 million on December 31, 2020[52]. - The company secured bank loans amounting to approximately RMB 95 million, with collateral provided by properties valued at approximately RMB 24.47 million and RMB 2.45 million[54]. - Total assets as of June 30, 2021, amounted to RMB 383,492 thousand, slightly down from RMB 386,516 thousand as of December 31, 2020[68]. - Current liabilities totaled RMB 368,933 thousand as of June 30, 2021, compared to RMB 378,866 thousand as of December 31, 2020, indicating a decrease of 2.5%[70]. - The company reported a net asset value of RMB 201,456 thousand as of June 30, 2021, an increase from RMB 196,271 thousand as of December 31, 2020[70]. - The company’s cash and cash equivalents decreased to RMB 22,854 thousand as of June 30, 2021, from RMB 45,453 thousand as of December 31, 2020[68]. - The net cash inflow from operating activities for the six months ended June 30, 2021, was RMB 25,353,000, compared to a net cash outflow of RMB 9,290,000 for the same period in 2020[74]. Employee and Management - The total employee cost for the six months ended June 30, 2021, was approximately RMB 38.6 million, compared to RMB 39.31 million in the same period of 2020[57]. - As of June 30, 2021, the company employed approximately 415 full-time employees, a decrease from about 450 employees as of December 31, 2020[57]. - Total remuneration for key management personnel increased to RMB 2,985,000 for the six months ended June 30, 2021, compared to RMB 2,152,000 in the previous year[107]. Shareholder Information - The major shareholder, Beijing Saipu Asset Management Co., Ltd., is a wholly-owned subsidiary of the Chinese Academy of Sciences, providing a strong foundation for the company's research capabilities[27]. - Beijing Puxi Asset Management Co., Ltd. holds 31,308,576 shares, representing 38.93% of the domestic shares and 21.64% of the total registered capital[29]. - Mr. Xiao Yonggang directly owns 7,763,505 shares, accounting for 9.65% of the domestic shares and 5.36% of the total registered capital[29]. - Beijing Holdings Limited holds 27,256,143 H shares, which is 42.40% of the H shares and 18.84% of the total registered capital[29]. - Yunnan Shengneng Investment Partnership holds 6,780,000 H shares, representing 10.55% of the H shares and 4.69% of the total registered capital[29]. - Chung Shek Enterprises Company Limited owns 3,800,000 H shares, accounting for 5.91% of the H shares and 2.63% of the total registered capital[29].

Financial Performance - For the first quarter of 2021, the company reported revenue of RMB 80,894,000, a significant increase of 72% compared to RMB 47,089,000 in the same period of 2020[14] - The gross profit for the first quarter of 2021 was RMB 35,304,000, compared to RMB 14,311,000 in the first quarter of 2020, reflecting a gross margin improvement[14] - The net profit for the first quarter of 2021 was RMB 405,000, a recovery from a net loss of RMB 17,464,000 in the same quarter of the previous year[14] - The company’s operating loss decreased to RMB 1,842,000 in the first quarter of 2021 from a loss of RMB 2,723,000 in the same quarter of 2020[14] - The total comprehensive income for the first quarter of 2021 was RMB 421,000, compared to a loss of RMB 17,531,000 in the same period of 2020[16] - The company reported a basic and diluted loss per share of RMB 0.01 for the first quarter of 2021, an improvement from a loss of RMB 0.11 per share in the same quarter of 2020[14] - The loss attributable to shareholders for the three months ended March 31, 2021, was RMB 0.65 million, a 96% reduction from a loss of RMB 15.80 million in the same period last year[36] - The total comprehensive income for the three months ended March 31, 2021, was a loss of RMB 15.86 million, reflecting the impact of operational challenges[31] Research and Development - The company incurred research and development expenses of RMB 5,800,000 in the first quarter of 2021, compared to RMB 5,279,000 in the same period of 2020[14] - The company is committed to ongoing research and development to innovate and improve its product line[19] - The company is focusing on the development of in vitro diagnostic products and services, aiming to enhance its competitive edge through independent research and development[40] - The company aims to enhance its product quality and continuously develop new testing projects in response to industry technological advancements[40] Market Presence and Strategy - The company aims to continue expanding its market presence and enhancing its product offerings in the in vitro diagnostic sector[19] - The domestic in vitro diagnostic reagent market still sees over 50% demand from biochemical and immunodiagnostic reagents, indicating a significant market share[38] - The company anticipates that the domestic health industry will continue to grow due to factors such as an aging population and increased health awareness[37] Corporate Governance - The company has complied with all provisions of the Corporate Governance Code, except for specific provisions A.1.8 and C.2.5[55] - The audit committee, consisting of three independent non-executive directors, reviewed the unaudited consolidated income statement for the period[54] - The company confirms that all directors have complied with the standards of conduct for securities trading during the reporting period[50] - As of March 31, 2021, there are no reported interests or conflicts of interest among directors, supervisors, and management that could compete with the company's business[52] Shareholder Information - As of March 31, 2021, Mr. Wu Le Bin holds 3,500,878 shares, representing 4.35% of the company's domestic shares and 2.42% of the total registered capital[43] - Major shareholder Beijing Puxi Asset Management Co., Ltd. owns 31,308,576 domestic shares, accounting for 38.93% of the domestic shares and 21.64% of the total registered capital[45] - Mr. Wang Tao directly holds 24,506,143 shares, which is 30.47% of the domestic shares and 16.93% of the total registered capital[45] Internal Controls and Risk Management - The company has decided not to establish an internal audit department due to its scale and operational structure, but has implemented measures for risk management and internal control[59] - The company is currently reviewing insurance quotes to purchase liability insurance for its directors within 2021[58] Dividend Policy - The company does not recommend the distribution of an interim dividend for the three months ended March 31, 2021[32] Product Registration - The company completed the continuation registration of 67 products, including the lipoprotein (a) assay kit (immunoturbidimetric method), and obtained a Class I product filing for cleaning agents[40] Taxation - The company has maintained a 15% preferential tax rate due to its classification as a high-tech enterprise, compared to the standard 25% corporate income tax rate in China[4]